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ABSTRACT 
PURPOSE 
The purpose of this study was to characterize the CDI population at this institution according to known 
risk factors and to examine the effect of appropriate evidence-based treatment selection on length of 
patient stay and outcome of infection. 
METHODS 
The institutional review board at the study facility approved this retrospective, observational study. All 
patients at least 18 years of age with a positive Clostridium difficile toxin test by enzyme-linked 
immunosorbent assay (ELISA) from January to December 2011 were included in this study. The 
electronic medical records of patients meeting inclusion criteria were reviewed for both patient specific 
and medication associated risk factors. Secondly, the medical record was utilized to assign disease 
severity and assess corresponding appropriateness of treatment for each documented CDI occurrence 
according to IDSA/SHEA criteria. Finally, the effect of appropriate treatment on patient length of stay 
and infection outcome was analyzed. 
RESULTS 
Over 96 percent of patients had more than one risk factor for CDI in this study. The effect of appropriate 
treatment on patient outcome, specifically resolution of infection versus recurrence or patient death, 
was assessed by chi-square test. A significant increase in treatment failure was observed in patients who 
did not receive the appropriate regimen according to IDSA/SHEA recommendations. However, the 
potential for confounding by indication was then examined by controlling for infection severity. The 
analysis revealed that there was in fact no significant difference in patient outcome regardless of the 
initial CDI treatment chosen. The relationship between appropriate initial treatment and length of stay 
was not significant, regardless of whether deaths were excluded from the data set. 
CONCLUSION 
Adherence to IDSA guidelines did not have a significant impact on patient outcomes associated with CDI 
including length of stay, treatment failure, and mortality. 
  
BACKGROUND 
 Clostridium difficile is the most frequently encountered nosocomial pathogen in community 
hospitals in the United States. Increased use of flouroquinolones and the emergence of the 
hypervirulent BI/NAP1/027 strain have been linked to an increase in Clostridium difficile infection (CDI) 
frequency and severity, as well as a shift in the epidemiology of CDI. The most dramatic increase in 
infection rate has been observed in patients 65 years of age or older but formerly low-risk populations, 
including peripartum women and young members of the community, are increasingly vulnerable to CDI. 
Perhaps most importantly, the CDI-associated mortality rate has increased more than 400 percent since 
the year 2000.1 Up to 3% of adults may be asymptomatic carriers.2 In the past 10 years, an emergent 
hypervirulent C. difficile clonal group has been attributed to increasing morbidity and mortality rates 
worldwide. Over the 5-year period from 1999 to 2004, associated mortality increased from 5.7 to 23.7 
deaths per 1 million persons globally. The strain is known as North American Pulsed Field type 1(NAP1), 
restriction-endonuclease analysis (REA) type B1, polymerase-chain-reaction ribotype 027 or collectively 
as NAP1/B1/027. The strain is highly resistant to flouroquinolones.3 Patients typically respond well to 
treatment with either oral vancomycin or metronidazole. However, the cost of treatment with 
vancomycin and presence of resistant bacterial strains may give preference to metronidazole 
utilization.2 Recurrence rates with both drugs are increasingly high. 
 C. difficile is an anaerobic, gram-positive, rod-shaped bacterium. Its ability to produce spores 
allows any surface to become a reservoir with high-risk fomites such as thermometers, blood pressure 
cuffs and inadequately cleaned bedpans or toilets commonly associated with CDI outbreaks. It is spread 
through the fecal-oral route, often as spores present on the hands of healthcare workers.  The risk of 
CDI increases with increased length of hospital stay. It produces 2 exotoxins, toxin A and toxin B, with 
symptoms appearing 2 to 3 days after infection. C. difficile is present in many healthy adults with the 
disease course ranging from asymptomatic carriage to fatal pseudomembranous colitis.3 A diagnosis of 
Clostridum difficile infection (CDI) is defined by the presence of symptoms and either a positive stool 
test or pseudomembranous colitis, confirmed by colonoscopy. Most patients with CDI were treated with 
antimicrobial or antineoplastic agents in the previous 8 weeks. Additional risk factors include female sex, 
age > 64, previous gastrointestinal surgery, use of histamine-2 antagonists or proton pump inhibitors, 
and HIV infection. Antimicrobial use is the most modifiable risk factor for CDI, with longer duration of 
use being associated with an increased risk of infection.1,3 
 In May 2010, the Infectious Diseases Society of America and the Society for Healthcare 
Epidemiology generated the updated treatment guidelines for C. difficile. The guidelines indicate that 
the first-line treatment of choice should depend on disease severity. Oral metronidazole is considered 
the first-line treatment for an initial episode of mild-to-moderate CDI. In cases of severe CDI, oral 
vancomycin is the drug of choice. A combination regimen of oral vancomycin, rectal vancomycin and/or 
intravenous metronidazole is indicated in severe, complicated CDI.  The same initial therapy should be 
used for the first recurrence, but metronidazole cannot be used thereafter. Vancomycin is the preferred 
treatment for patients with multiple instances of CDI.3 
 The exact reason for recurrence of CDI has not been determined. Factors believed to be 
associated with recurrent disease include disruption of the normal intestinal flora, antibiotic-induced 
bowel changes that decrease natural resistance to colonization and an impaired immune response to 
C.difficile and its toxins. Up to 30% of CDI patients will experience a recurrence of infection, often within 
the first 2 weeks after completion of initial treatment. Patients experiencing such a recurrence have a 
45% chance of additional recurrences of CDI.1 
 Reduced rates of clinical response to treatment coupled with increasing rates of recurrence, 
mortality and incidence in low-risk populations make the research and development of effective CDI 
treatment protocols imperative. The recently updated guidelines for treatment of CDI call for the 
evaluation of 3 major outcomes when comparing drug therapy: time to symptom resolution, incidence 
of recurrence, and the frequency of major complications.3 This study will examine all of the cases of CDI 
at our institution over a 12-month period. The updated treatment guidelines, current practice outcomes 




 The institutional review board at the study facility approved this retrospective, observational 
study. All patients at least 18 years of age with a positive Clostridium difficile toxin test by enzyme-linked 
immunosorbent assay (ELISA) from January to December 2011 were included in this study. The 
electronic medical records of patients meeting inclusion criteria were reviewed for both patient specific 
and medication associated risk factors. Documented risk factors included advanced age, male gender, 
diabetes, and pregnancy in addition to recent utilization of antibiotics, proton pump inhibitors, or 
immunosuppressant agents. Secondly, the medical record was utilized to assign disease severity and 
assess corresponding appropriateness of treatment for each documented CDI occurrence according to 
IDSA/SHEA criteria (Table 1). Severity data including degree of leukocytosis, increase in serum 
creatinine, and presence of shock or ileus were collected. As outlined by the IDSA, these criteria were 
then used to categorize each CDI as mild or moderate, severe, or severe and complicated. The number 
of prior episodes of CDI was also noted for each case. Once categorized, the initial treatment for each 
CDI episode was documented and assessed for adherence to IDSA/SHEA guidelines 3.  
STATISTICAL ANALYSIS 
 Descriptive statistics were used to describe CDI risk factors present in the patient cohort. The 
effect of appropriate treatment on patient length of stay and infection outcome was analyzed. Infection 
outcome was classified as successful treatment, treatment failure, or death with differences assessed by 
chi-square test. Effect of treatment on length of stay, both including and excluding patients who died 
was analyzed using both a student’s t-test and a Wilcoxon rank sum test. A Fisher’s exact test was used 
during the assessment of potential confounders. 
RESULTS 
BASELINE CHARACTERISTICS 
 Epidemiological factors of the CDI cohort were determined with most cases falling into the 
healthcare-facility acquired, community-onset subgroups (Table 2). Additionally, 55% of patient had 
mild-to-moderately severe disease according to IDSA guidelines.  Over 96 percent of patients had more 
than one risk factor for CDI in this study (Table 3). The most common risk factors were antibiotic use 
(81.6%) and proton pump inhibitor use (56.3%) in the 90-day period before index date.  
EFFECT OF GUIDELINE ADHERENCE ON PATIENT OUTCOMES 
 The effect of appropriate treatment on patient outcome, specifically resolution of infection 
versus recurrence or patient death, was assessed by chi-square test. A statistically significant increase in 
treatment failure was observed in patients who did not receive the appropriate regimen according to 
IDSA/SHEA recommendations (p = 0.0250, Table 4). No significant increase in patient mortality rate was 
observed. The relationship between appropriate initial treatment and length of stay was not significant, 
regardless of whether deaths were excluded from the data set (p = 0.0594, Table 5). However, it 
appeared that physicians at this institution automatically placed patients with a positive CDI toxin result 
on oral metronidazole regardless of the severity of patient’s CDI. This could potentially increase the 
number of patients with mild-to-moderate disease who received the correct initial CDI treatment 
according to IDSA guidelines. The potential for confounding by indication was then examined by 
controlling for infection severity. The analysis revealed that there was in fact no significant difference in 
patient outcome regardless of the initial CDI treatment chosen (p = 0.4096, Table 6). There appears to 
be a relationship between treatment adherence and patient outcome for patients with severe disease 
but the sample size was too small to detect a difference. Additionally, the results in the severe and 
complicated category indicate that there is little association between adherence to guidelines and 
patient outcome.  
DISCUSSION 
 There are many potential limitations to this study including the retrospective design and lack of 
randomization, a multitude of potential covariates, limited patient follow-up time, and limited available 
data for some patients prior to admission. However, this study is consistent with the strengths of the 
recommendations provided by the IDSA CDI guidelines. The recommended treatment for patients in the 
severe and complicated category is a C-III recommendation and it is not surprising that no relationship 
was found between guideline adherence and patient outcome in this study. 
CONCLUSION 
Adherence to the 2010 IDSA/SHEA guidelines for management of CDI did not have a significant effect on 
patient outcome or length of stay in this study. Although there appeared to be a positive relationship 
between guideline adherence and treatment outcome, particularly in the mild or moderate and severe 
CDI classification groups, the results were not significant when the analysis was controlled for infection 
severity. Large trials designed to overcome many potential confounders are needed in order to provide 
evidenced-based guidelines for treatment of all classifications of CDI.  
Table 1: Assessment of Disease Criteria 
DISEASE SEVERITY CRITERIA 
MILD-MODERATE WBC <15,000 CELLS/µL  
AND 
SERUM CREATININE  <1.5X BASELINE 
SEVERE WBC ≥15,000 CELLS/µL  
OR 
SERUM CREATININE ≥1.5X BASELINE 






Table 2: Epidemiological Factors 
CHARACTERISTIC N=87 
AGE (YR), MEAN±SD 69±19.6 
FEMALE GENDER (%) 57.5 
PREVIOUS EPISODE OF C.DIFFICILE INFECTION, N (%) 14 (16.1%) 
SEVERITY OF DISEASE AT BASELINE, N (%)  
MILD-TO-MODERATE 48 (55.2%) 
SEVERE 21 (24.1%) 
SEVERE AND COMPLICATED 18 (20.7%) 
PLACE OF CDI ACQUISITION, N (%)  
COMMUNITY-ACQUIRED 33 (37.9%) 
HEALTHCARE-FACILITY ACQUIRED 38 (43.7%) 
INDETERMINATE 16 (18.4%) 
PLACE OF CDI ONSET, N (%)  
COMMUNITY-ONSET 53 (60.9%) 
HEALTHCARE-FACILITY ONSET 18 (20.7%) 
INDETERMINATE 16 (18.4%) 
 
  
Table 3: Patient risk factors for CDI 
FACTOR INCIDENCE, N (%) 
MALE GENDER 37 (42.5%) 
COMORBID CONDITIONS IN THE 2-YEAR PERIOD BEFORE INDEX DATE 
INFLAMMATORY BOWEL DISEASE 13 (14.9%) 
GASTROINTESTINAL MANIPULATION 28 (32.2%) 
GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE 0 
DIABETES 16 (18.3%) 
SOLID-ORGAN TRANSPLANT 1 (1.1%) 
MALIGNANCY 23 (26.4%) 
HIV 0 
CONCOMITANT BLOOD INFECTION 5 (5.7%) 
PREGNANCY 2 (2.3%) 
MEDICATIONS RECEIVED IN THE 90-DAY PERIOD BEFORE INDEX DATE 
ANTIBIOTIC 71 (81.6%) 
PROTON PUMP INHIBITOR 49 (56.3%) 
H2-RECEPTOR ANTAGONIST 25 (28.7%) 
SUCRALFATE 5 (5.7%) 
IMMUNOSUPPRESSANT AGENT 10 (11.5%) 
 >1 RISK FACTOR FOR C.DIFFICILE INFECTION, N (%) 84 (96.6%) 
 
Table 4: Effect of appropriate treatment on patient outcome 
 APPROPRIATE INITIAL REGIMEN INAPPROPRIATE INITIAL 
REGIMEN 
P-VALUE* 
SUCCESSFUL TREATMENT 93.33% 76.19%  
TREATMENT FAILURE 6.67% 23.81% 0.0250 
DEATH 4.44% 16.67% 0.0614 
*CHI-SQUARE TEST 
Table 5: Effect of appropriate treatment on patient length of stay (LOS) 






MEAN LOS (SD), DEATHS EXCLUDED 8.81 DAYS ± 8.89 15.03 DAYS ± 18.9 0.0594 
MEAN LOS (SD), DEATHS INCLUDED 8.88 DAYS ± 8.92 14.76 ± 17.72 0.0518 
*T-TEST, [WILCOXAN RANK SUM TEST P=0.0681]  
++ MUCH MORE VARIANCE IN LOS OF PATIENTS WHO RECEIVED APPROPRIATE TREATMENT, P <0.0001 
  
Table 6: Effect of appropriate treatment when controlled for disease severity 
MILD-TO-MODERATE APPROPRIATE INITIAL REGIMEN INAPPROPRIATE INITIAL 
REGIMEN 
P-VALUE* 
SUCCESSFUL TREATMENT 97.30% 90.91%  
TREATMENT FAILURE 2.70% 9.09% 0.4096 
DEATH 2.70% 0% 1.0000 
SEVERE    
SUCCESSFUL TREATMENT 100% 72.22%  
TREATMENT FAILURE 0% 27.78% 0.5489 
DEATH 0% 22.22% 1.0000 
SEVERE AND COMPLICATED++ APPROPRIATE INITIAL REGIMEN INAPPROPRIATE INITIAL 
REGIMEN 
P-VALUE 
SUCCESSFUL TREATMENT 60.00% 69.23%  
TREATMENT FAILURE 40.00% 30.77% 1.0000 
DEATH 20.00% 23.08% 1.0000 
*FISHER’S EXACT TEST 
++THERE APPEARS TO BE NO RELATIONSHIP IN THIS SEVERITY CATEGORY AT ALL; POSSIBLY DUE TO THE INTENSITY OF ILLNESS 
OF THESE PATIENTS. 
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